AIMT Aimmune Therapeutics, Inc.

19.65
0  -1%
Previous Close 19.75
Open 19.86
Price To book 3.47
Market Cap 987.39M
Shares 50,249,000
Volume 173,592
Short Ratio 10.54
Av. Daily Volume 328,708

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 4Q 2017.
AR101
Peanut Allergy

Latest News

  1. Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
  2. Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
  3. Edited Transcript of AIMT earnings conference call or presentation 15-Mar-17 12:00pm GMT
  4. Aimmune Therapeutics reports 4Q loss
  5. Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
  6. Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
  7. Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
  8. Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
  9. Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
  10. Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
  11. Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  12. Hedge Funds Aren’t Crazy About Aimmune Therapeutics Inc (AIMT) Anymore
  13. Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
  14. Aimmune Closes Enrolment in Phase III Peanut Allergy Study
  15. Aimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  16. Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
  17. Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
  18. Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
  19. Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update